Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02542267 · ClinicalTrials.gov registry record · NA
In-Stent Restenosis Post-Approval Study
A NA study, sponsored by W.L.Gore & Associates.
- Completed
- Registry status
- NA
- Development phase
- 108
- Enrollment target
NCT02542267 is a NA study that has completed, run by W.L.Gore & Associates. The registered enrollment target is 108 participants.
The verdict
NCT02542267, a NA study, has completed, sponsored by W.L.Gore & Associates.
- COMPLETED
- Registry status
- NA
- Development phase
- 108 participants
- Enrollment target
Study Summary
The objective of the ISR 14-04 study is to evaluate post-market safety and effectiveness of GORE® VIABAHN® Endoprosthesis for treatment of In-Stent Restenosis of the Superficial Femoral Artery.
Interventions
- DEVICE Gore VIABAHN Endoprosthesis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2015-09 |
| Est. Completion | 2021-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02542267
The ClinicalTrials.gov registry entry for NCT02542267 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is W.L.Gore & Associates, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gore VIABAHN Endoprosthesis is the first listed.
NCT02542267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02542267 about?
NCT02542267 is a clinical study titled "In-Stent Restenosis Post-Approval Study". The objective of the ISR 14-04 study is to evaluate post-market safety and effectiveness of GORE® VIABAHN® Endoprosthesis for treatment of In-Stent Restenosis of the Superficial Femoral Artery.
What is the current status of trial NCT02542267?
This trial is currently completed. It is a NA study. The enrollment target is 108 participants. The study started on 2015-09. Estimated completion is 2021-07.
What interventions are being tested in trial NCT02542267?
The interventions under investigation include: Gore VIABAHN Endoprosthesis (DEVICE).
Who is sponsoring clinical trial NCT02542267?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.